Added to YB: 2025-01-16
Pitch date: 2025-01-14
CDXC [bullish]
Niagen Bioscience, Inc.
+14.77%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Market Cap
$512.6M
Pitch Price
$5.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.10
P/E
27.25
EV/Sales
3.62
Sector
Life Sciences Tools and Services
Category
growth
Show full summary:
ChromaDex ($CDXC), a trending NAD+ company and Bryan Johnson beneficiary!
CDXC: NAD+ supplement leader, 31% YoY rev growth, 63.5% margins. Viral TikTok/celeb trend. 375+ studies, 31 human trials. Expanding to 300+ clinics ($300-$2k/session). Phase III Ataxia-Telangiectasia orphan drug trial ends May 2025. Parkinson's research ongoing. $32.4M cash, no debt. Asymmetric upside potential.